| Day 1 – Friday, October 23, 2026 | |
|---|---|
| 09:00-09:10 (Europe Time) |
Welcome and vision for the congress Ricardo Grieshaber-Bouyer, Arnon Nagler, and Dror Mevorach |
| 09:10-11:10 | Session 1: From haemato-oncology to autoimmunity Chairs: Arnon Nagler & Raffaella Greco |
| 09:10-09:40 | Current European guidelines for HSCT and CAR T in autoimmune diseases. TBA |
| 09:40-10:10 | Safety in CAR T and bispecific antibodies in hemato-obcology. TBA |
| 10:10-10:40 | CAR T and bispecific comparative safety in autoimmune diseases. Henrik Schulze-Koops, Munich |
| 10:40-11:10 | Antigen-specific CAR T cell therapy. Christoph Ellebrecht, Philadelphia |
| 11:10-12:40 | Session 2: Academic CAR T in autoimmunity Chairs: TBA & Dror Mevorach |
| 11:10-11:40 | CAR T BCMA: A single academic center experience in autoimmunity. TBA |
| 11:40-12:10 | CAR T CD19: A single academic center experience in autoimmunity. Merav Lidar, Tel-Aviv |
| 12:10-12:40 | Academic CAR T, commercial CAR-T or both? TBA |
| 12:40-14:10 | Session 3: Bispecific in autoimmunity: Present and Future Chairs: Ricardo Grieshaber-Bouyer & Melanie Hagen |
| 12:40-13:10 | New applications for autoimmunity of bispecific and trispecific antibodies. TBA |
| 13:10-13:40 | Supercharging monoclonal antibodies with allogeneic NK cells. TBA |
| 13:40-14:10 | CAR T or BiTE for autoimmunity? Ricardo Grieshaber-Bouyer, Erlangen |
| 14:10-15:40 | Session 4: What have we learned from B cell targeting about pathophysiology of autoimmunity Chairs: Dror Mevorach & Danae Noethling |
| 14:10-14:40 | SLE revisited William Robinson, Stanford |
| 14:40-15:10 | Scleroderma revisited TBA |
| 15:10-15:40 | B cell targeting nephrological diseases TBA |
| 15:40-16:10 | Session 5: Pioneers of CAR T therapy Chair: Ricardo Grieshaber-Bouyer & Dror Mevorach |
| 15:40-16:50 | Plenary lecture: History & Future of CAR T cell therapy: Michel Sadelain, New York |
| 16:50-17:30 | Questions and answers |
| Day 2 – Saturday, October 24, 2026 | |
|---|---|
| 09:00-11:00 | Session 6: Near future perspectives I Chairs: Patrick Baeuerle & Christoph Ellebrecht |
| 09:00-09:30 | Comparison between CAR-BCMA and CAR CD19 in autoimmunity Attilio Bondanza, AstraZeneca |
| 09:30-10:00 | Allogeneic versus autologous CAR T TBA |
| 10:00-10:30 | B cell targeting in autoimmune liver diseases Richard Taubert, Hannover |
| 10:30-11:00 | B cell targeting antiphospholipid syndrome and rare diseases Dror Mevorach, Jerusalem |
| 11:00-13:40 | Session 7: 5 years of CAR-T- and T-cell engagers in autoimmunity Chairs: TBA & David Simon |
| 11:00-11:30 | SLE: How do you choose the right patient for Cellular and Humoral Therapy? Thomas Dörner, Berlin |
| 11:30-12:00 | Rheumatoid arthritis: How do you choose the right patient for Cellular and Humoral Therapy? Gerhard Krönke, Berlin |
| 12:00-12:30 | Scleroderma: How do you choose the right patient for Cellular and Humoral Therapy? Hanns-Martin Lorenz, Heidelberg |
| 12:30-13:00 | Myositis: How do you choose the right patient for Cellular and Humoral Therapy? TBA |
| 13:00-15:45 | Session 8: Near future perspectives II Chairs: Gerhard Krönke & William Robinson |
| 13:00-13:30 | Next generation precision cell depletion for autoimmune diseases TBA |
| 13:30-14:00 | Advanced CAR T: In Vivo CAR T: TBA |
| 14:00-14:30 | Panel Debate Autologous Vs. Heterologous CAR T TBA |
| 14:30-15:00 | Panel Debate CAR T or BiTE for autoimmunity? TBA |
| 15:00 | Closing remarks Dror Mevorach, Arnon Nagler and Ricardo Grieshaber-Bouyer |
